HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT

Cancer Research

Volumn 74, Issue 6, 2014, Pages 1728-1738

  Noh, Ji Heon ^a,c   Bae, Hyun Jin ^a,c   Eun, Jung Woo ^a,c   Shen, Qingyu ^a,c   Park, Se Jin ^a,c   Kim, Hyung Seok ^a,c   Nam, Boas ^a,c   Shin, Woo Chan ^a,c   Lee, Eun Kyung ^a,b   Lee, Kyungbun ^d   Jang, Ja Jun ^d   Park, Won Sang ^a,c   Lee, Jung Young ^a,c   Nam, Suk Woo ^a,c  

^a The Catholic University of Korea   (South Korea)

^b Graduate Institute of Medicine   (United States)

^c Functional RNomics Research Center   (United States)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NUCLEAR FACTOR KAPPA B SUBUNIT P50; PHOSPHATIDYLINOSITIDE; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; HDAC2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METASTASIS POTENTIAL; MITOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POSITIVE FEEDBACK; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; FEEDBACK, PHYSIOLOGICAL; HEP G2 CELLS; HISTONE DEACETYLASE 2; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICE; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NF-KAPPA B P50 SUBUNIT; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME;

EID: 84896512186     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2109     Document Type: Article

References (19)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87. (Pubitemid 44286000)
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245-55.
3. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83, 83 e1-11.
4. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005.
5. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
6. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-32. (Pubitemid 47255924)
7. Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, et al. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 2011;6:e28103.
8. Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, et al. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem 2012;113:2167-77.
9. Kim JK, Noh JH, Eun JW, Jung KH, Bae HJ, Shen Q, et al. Targeted Inactivation of HDAC2 Restores p16INK4a Activity and Exerts Antitumor Effects on Human Gastric Cancer. Mol Cancer Res 2013;11: 62-73.
10. Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Chang YG, et al. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-Terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer. Hepatology 2012;56: 644-57.
11. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010;27:255-61.
12. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
13. Vinciguerra M, Veyrat-Durebex C, Moukil MA, Rubbia-Brandt L, Rohner-Jeanrenaud F, Foti M. PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 2008;134:268-80. (Pubitemid 350309315)
14. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 2007;9:443-54. (Pubitemid 46799988)
15. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
16. Chen XG, Liu F, Song XF, Wang ZH, Dong ZQ, Hu ZQ, et al. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol Carcinog 2010;49:603-10.
17. Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, et al. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 2012;57:108-15.
18. Chou CW, Wu MS, Huang WC, Chen CC. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 2011;6: e18087.
19. Bicaku E, Marchion DC, Schmitt ML, Munster PN. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 2008;68:1513-9. (Pubitemid 351346860)